NETRIS Pharma Press Releases

• Published on September 18, 2025 - 06:00 GMT

  NETRIS Pharma appoints Dr. Sébastien Hazard as Chief Medical Officer to Lead Next Phase of Clinical Development

  NETRIS Pharma is advancing its pipeline into later-stage clinical trials LYON, FRANCE, September 18, 2025 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage biotechnology company developing first-in-class therapeutics targeting Netrin-1 and its role …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on April 25, 2025 - 06:00 GMT

  

  NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1

  Confirmation of NP137 Potential to Overcome Resistance to Immune Checkpoint - Clinical Trial Design and Interim Results to be Presented at ASCO and ESMO 2025 LYON, FRANCE, April 25, 2025 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage private …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on December 3, 2024 - 07:00 GMT

  

  NETRIS Pharma Welcomes Eric Falcand as Independent Director to Its Board of Directors

  LYON, FRANCE AND GENEVA , SWITZERLAND, December 3, 2024 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a leading clinical-stage biopharmaceutical company dedicated to advancing the next generation of molecules targeting cancer resistance, today announced the …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on November 21, 2024 - 07:00 GMT

  

  NETRIS Pharma Announces FDA Orphan Drug Designation (ODD) for NP137 in Pancreatic Cancer Treatment

  LYON, FRANCE, AND GENEVA, SWITZERLAND, November 21, 2024 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage biopharmaceutical company pioneering therapies to overcome resistance in oncology, today announced that the U.S. Food and Drug Administration ( …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on September 4, 2024 - 06:00 GMT

  

  NETRIS Pharma appoints Segolène BISOT-LOCARD as Chief Medical Officer

  NETRIS Pharma poised to advance into the next phase of clinical development LYON, FRANCE, September 4, 2024 /⁨EINPresswire.com⁩/ -- LYON, France and GENEVA, Switzerland– NETRIS PHARMA today announced the appointment Ségolène BISOT-LOCARD, MD, as Chief …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on May 23, 2024 - 06:00 GMT

  

  NETRIS Pharma awarded €3.9m to Lead the Development of a Novel Therapy in Endometriosis

  EndoNETherapy aims at delivering the First Non-Hormonal Disease Modifying Therapy for patients suffering from Endometriosis LYON, RHONE, FRANCE, May 23, 2024 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage private biopharmaceutical company …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on December 19, 2023 - 07:00 GMT

  

  NETRIS Pharma extends Series A to €24.4 million and reinforces its leadership team and Board of Directors

  Proceeds of €7.5m to enable the completion of 5 ongoing phase 2 clinical studies LYON, FRANCE, December 19, 2023 /⁨EINPresswire.com⁩/ -- NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on August 30, 2023 - 06:00 GMT

  

  NETRIS Pharma: data published in 2 Nature papers confirm netrin-1 blockade as significant clinical strategy in oncology

  Netrin-1 blockade with NP137 confirmed as a clinical strategy in oncology to alleviate resistance to standard treatments LYON, FRANCE, August 30, 2023 /⁨EINPresswire.com⁩/ -- > Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...